erlotinib hydrochloride has been researched along with Head and Neck Neoplasms in 148 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.68) | 18.2507 |
| 2000's | 44 (29.73) | 29.6817 |
| 2010's | 87 (58.78) | 24.3611 |
| 2020's | 16 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Agca, S; Arabaci, DH; Bilgic, SN; Domaniku, A; Kir, S; Weber, BZC | 1 |
| Chan, CY; Chang, CM; Chen, YH; Hong, SC; Huang, CY; Liao, PC | 1 |
| Csala, M; Csámpai, A; Duró, C; Gurbi, B; Móra, I; Murányi, J; Németh, K; Simon, J; Varga, A | 1 |
| Dave, H; Hariharan, K; Mehta, T; Omri, A; Sami, A; Shah, J | 1 |
| Dorna, D; Frąckowiak, M; Kleszcz, R; Paluszczak, J | 1 |
| Barrett, JW; Dhaliwal, SS; Fung, K; Howlett, CJ; Khan, MI; MacNeil, D; Mymryk, JS; Nichols, AC; Pinto, N; Plantinga, P; Ruicci, KM; Stecho, W; Yoo, J | 1 |
| Bartels, J; Betz, CS; Buhs, S; Bußmann, L; Clauditz, TS; Gerull, H; Hoffer, K; Kriegs, M; Münscher, A; Nollau, P; Petersen, C; Rieckmann, T; Rothkamm, K; Struve, N; Zech, HB | 1 |
| Aderhold, C; Birk, R; Huber, L; Kramer, B; Mueller, CE; Rotter, N; Schell, A | 1 |
| Chan, CY; Chang, CM; Chen, YH; Huang, CY; Lin, TY; Sheu, JJ | 1 |
| Han, Y; Hu, J; Ju, H; Liu, L; Liu, S; Ren, G; Wang, Y; Xia, W; Xu, S; Ye, W; Zhang, L; Zhang, X; Zhang, Z | 1 |
| Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; El-Deiry, MW; Khuri, FR; Klein, AM; Liu, Y; Nannapaneni, S; Owonikoko, TK; Patel, MR; Ramalingam, SS; Roser, SM; Saba, NF; Shi, Q; Shin, DM; Steuer, CE | 1 |
| Baxter, MA; Petty, RD; Spender, LC | 1 |
| Baumann, H; Cacaccio, J; Cheruku, RR; Dukh, M; Durrani, FA; Guru, K; Kalinski, P; Koya, RC; Missert, JR; Pandey, RK; Siters, K; Tabaczynski, WA; Tracy, EC; Watson, R | 1 |
| Lee, J; Roh, JL; You, JH | 1 |
| Barbai, T; Cserepes, M; Dobos, J; Hegedűs, Z; Kárpáti, A; Kenessey, I; László, V; Nelhűbel, GA; Őrfi, L; Rásó, E; Szabó, B; Szokol, B; Tóvári, J; Türk, D | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Paluszczak, J; Skalski, M | 1 |
| Chatterjee, A; Gowda, H; Jain, AP; Keshava Prasad, TS; Kumar, M; Mathur, PP; Nanjappa, V; Patel, K; Pinto, S; Radhakrishnan, A; Raja, R; Sidransky, D | 1 |
| Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD | 1 |
| Ding, X; Dong, Y; Gu, W; Song, X; Wang, Z; Wu, Y; Zhang, W; Zheng, Y; Zhong, Y | 1 |
| Fang, S; Hu, J; Jin, S; Ma, H; Yang, W; Zhang, Z; Zhao, M; Zhou, G | 1 |
| Baik, C; Baker, KK; Chow, LQ; Eaton, K; Goulart, BH; Guerriero, MK; Lee, S; Martins, RG; Redman, MW; Rodriguez, CP; Santana-Davila, R | 1 |
| Agarwal, V; Nayar, RC; Rao, V; Subash, A | 1 |
| Ather, F; Fejzo, MS; Finn, RS; Hamidi, H; Head, C; Kabbinavar, F; Letrent, S; Wong, SG | 1 |
| Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H | 1 |
| Austin, M; Bauman, JE; Chai, X; Eaton, KD; Futran, N; Hayes, DN; Kurland, BF; Liao, JJ; Martins, RG; Mendez, E; Papagikos, MA; Parvathaneni, U; Raez, LE; Schmidt, R; Sharma, AK; Wallace, SG; Wang, DX; Yunus, F | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Chalasani, P; Clausen, C; Dhiwakar, M; Kalapurakal, S; Malone, J; Rao, K; Robbins, KT; Robinson, K; Ronen, O; Shevlin, B | 1 |
| Case, AJ; Domann, FE; Fletcher, EV; Love-Homan, L; Miller, FJ; Raeburn, A; Schickling, BM; Simons, AL; Sobhakumari, A | 1 |
| Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Shin, DM; Sica, GL; You, S | 1 |
| Candy, PA; Epis, MR; Giles, KM; Goodall, GJ; Kalinowski, FC; Leedman, PJ; Redfern, AD; Stuart, LM; Zhang, PM | 1 |
| Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A | 1 |
| Austin, MC; Bauman, JE; Chai, X; Hayes, DN; Kurland, BF; Martins, RG; Mendez, E; Parvathaneni, U; Sampath, S; Schmidt, R; Vaezi, A | 1 |
| Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y | 1 |
| Andrews, GA; Byers, LA; Fooshee, DR; Frederick, MJ; Galer, C; Hah, JH; Heymach, J; Jasser, SA; Kim, E; Milas, ZL; Myers, JN; Papadimitrakopoulou, V; Pickering, CR; Sano, D; William, WN; Zhao, M | 1 |
| Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M | 1 |
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Wirth, LJ | 1 |
| Bansal, N; Center, B; Fetrow, JS; Furdui, CM; Kuremsky, JG; Marrs, GS; Mims, J; Olex, AL; Porosnicu, M; Qian, J; Tsang, AW; Wani, R; Yin, L; Zhao, W | 1 |
| Argiris, A; Bauman, JE; Chiosea, S; Conrads, TP; Denq, W; Ferris, RL; Flint, MS; Gooding, WE; Grandis, JR; Gross, ND; Hood, BL; Johnson, JT; Kim, S; Nikiforova, MN; Siegfried, JM; Sun, M; Thomas, SM; Wang, L; Wirth, L | 1 |
| Carroll, WR; Chung, TK; Clemons, L; Desmond, R; Nabell, L; Rosenthal, EL | 1 |
| Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI | 1 |
| Aoki, N; Celis, E; Harabuchi, Y; Kimura, S; Kobayashi, H; Kumai, T; Oikawa, K | 1 |
| Espinosa-Cotton, M; Koch, AT; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Chen, ZG; Haque, A; Khuri, FR; Rahman, MA; Ruhul Amin, AR; Saba, NF; Shin, DM | 1 |
| Espinosa-Cotton, M; Joseph, TS; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Einarson, MB; Golemis, EA; Jaffe, EK; Lawrence, SH; Liu, H; Nikonova, AS; Pecherskaya, A; Ramirez, UD; Robinson, MK; Serebriiskii, IG; Zhou, Y | 1 |
| Blumenschein, GR; Canales, JR; Ginsberg, LE; Heymach, JV; Kies, MS; Lee, JJ; Lin, H; Lu, C; Massarelli, E; Papadimitrakopoulou, V; Tran, HT; Williams, MD | 1 |
| Baay, M; Boeckx, C; De Pauw, I; Lardon, F; Peeters, M; Van den Bossche, J; Wouters, A | 1 |
| Amler, LC; Baselga, J; Blumenschein, GR; Bohórquez, SS; Calles, A; Cervantes, A; Dienstmann, R; Hidalgo, M; Jimeno, A; Juric, D; Kapp, AV; Leddy, C; Littman, C; Messersmith, W; Penuel, E; Pirzkall, A; Roda, D; Shames, DS; Tabernero, J; Wang, X | 1 |
| Bothwell, KD; Hershberger, PA; Johnson, CS; Kuriakose, MA; Merzianu, M; Seshadri, M; Shaurova, T; Suresh, A | 1 |
| Bauman, JE; Carter, SL; Chiosea, S; Close, D; Du, Y; Duvvuri, U; Egloff, AM; Garraway, LA; Getz, G; Gilbert, BR; Goetz, EM; Golub, TR; Grandis, JR; Johnson, JT; Johnston, PA; Li, H; Lui, VW; McKenna, A; Mills, GB; Pendleton, KP; Sougnez, C; Stransky, N; Van Allen, EM; Wagle, N; Wang, L; Zeng, Y; Zhang, F | 1 |
| Brands, RC; Hartmann, S; Kübler, AC; Linz, C; Müller-Richter, UD; Mutzbauer, G; Neckel, N; Seher, A | 1 |
| Dittmann, K; Fehrenbacher, B; Huber, S; Mayer, C; Paasch, A; Rodemann, HP; Schaller, M | 1 |
| Dikomey, E; Gleißner, L; Hoffer, K; Kriegs, M; Kwiatkowski, M; Myllynen, L; Petersen, C; Riepen, B; Rothkamm, K; Schlüter, H; Wurlitzer, M | 1 |
| Fu, P; Gibson, M; Lavertu, P; Machtay, M; Rezaee, R; Savvides, P; Sharma, N; Wasman, J; Woods, C; Yao, M; Zender, C | 1 |
| Mehra, R; Zibelman, M | 1 |
| Egloff, AM; Grandis, JR; Li, H; Lui, VW; Pendleton, KP; Wen, W; Wen, Y; Zeng, Y | 1 |
| Cao, W; Chen, Y; Ji, T; Lin, C; Lu, W; Ren, Z; Tang, Y; Wang, L; Wang, X; Yang, R; Zhang, C | 1 |
| Knudson, CM; Kowalski, CE; Love-Homan, L; Orcutt, KP; Parsons, AD; Simons, AL; Sobhakumari, A | 1 |
| Binder, M; Braig, F; Dikomey, E; Grénman, R; Hoffer, K; Kasten-Pisula, U; Kriegs, M; Myllynen, L; Petersen, C; Rieckmann, T; Riepen, B; Rothkamm, K; Struve, N | 1 |
| Ambrosetti, D; Benhamou, Y; Brolih, S; Chamorey, E; Lo Nigro, C; Merlano, M; Monteverde, M; Pagès, G; Picco, V; Raybaud, H; Sudaka, A | 1 |
| Ahn, PH; Anne, PR; Axelrod, RS; Cognetti, D; Dicker, AP; Keane, WM; Machtay, M; Wuthrick, E | 1 |
| Gibson-Corley, KN; Ihejirika, N; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Deng, X; Dohmae, N; Hamamoto, R; Kiyotani, K; Lingen, M; Matsuo, Y; Nakamura, Y; Park, JH; Saloura, V; Suzuki, T; Vougiouklakis, T; Zewde, M | 1 |
| Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C | 1 |
| Chen, Z'; Khuri, FR; Lee, JE; Shin, DM; Shin, HJ; Tighiouart, M; Yang, CS; Zhang, H; Zhang, X | 1 |
| Bozec, A; Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Milano, G; Sudaka, A | 1 |
| Agulnik, M; Wang, LX | 1 |
| Agulnik, M; Brockstein, B; Lacouture, M | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Choi, W; Haddad, Y; McConkey, DJ | 1 |
| Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL | 1 |
| Blair, E; Clark, JI; Cohen, EE; Dancey, JE; Davis, DW; Dekker, A; Karrison, TG; Kozloff, MF; Liu, W; Nattam, S; Pierce, C; Seiwert, TY; Stenson, K; Vokes, EE; Wong, SJ; Yan, DH | 1 |
| Brizel, DM | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Li, T; Perez-Soler, R | 1 |
| Amin, AR; Chen, ZG; Khuri, FR; Shin, DM | 1 |
| Benlyazid, A; Chatelut, E; Delord, JP; Hennebelle, I; Lefebvre, JL; Malard, L; Rochaix, P; Sarini, J; Thomas, F; White-Koning, M | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Cai, Q; Freilino, ML; Grandis, JR; Hahm, ER; Johnson, DE; Joyce, SC; Leeman-Neill, RJ; Li, C; Neill, DB; Panahandeh, MC; Seethala, RR; Sen, M; Singh, SV; Thomas, SM; Wheeler, SE | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Ahsan, A; Bhojani, MS; Hegde, A; Helman, A; Hiniker, SM; Lawrence, TS; Menawat, R; Nyati, MK; Nyati, S; Ramanand, SG | 1 |
| Bulj, TK; Cetner, AS; Krunic, AL; Villano, JL | 1 |
| Burtness, B; Chen, C; Cohen, R; Feigenberg, SJ; Jimeno, A; Kane, M; Lango, M; Mehra, R; Nicolaou, N; Raben, D; Ridge, J; Rusthoven, KE; Song, JI; Swing, R | 1 |
| Arbiser, JL; Bhola, NE; Cai, Q; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Neill, DB; Thomas, SM | 1 |
| Araújo, CM; Bezerra, M; Dias, FL; Federico, MH; Ferreira, CG; Fontão, K; Herchenhorn, D; Knust, RE; Martins, RG; Small, I; Viegas, CM | 1 |
| Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y | 1 |
| Allal, BC; Brillouet, S; Canal, P; Caselles, O; Courbon, F; Delord, JP; Filleron, T; Rochaix, P; Thomas, F; Vergez, S | 1 |
| Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME | 1 |
| Grazioso Russi, E; Numico, G; Silvestris, N | 1 |
| Chen, CT; Genden, EM; Gupta, V; Gurudutt, V; Kao, J; Misiukiewicz, K; Packer, SH; Rivera, M; Teng, M; Tong, CC | 1 |
| Goswami, P; Kalen, AL; Miller, FJ; Orcutt, KP; Parsons, AD; Scarbrough, PM; Sibenaller, ZA; Simons, AL; Sobhakumari, A; Spitz, DR; Wilke, WW; Zhu, Y | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Baumann, M; Bütof, R; Deuse, Y; Eicheler, W; Grenman, R; Gurtner, K; Krause, M; Oertel, R; Schaal, K; Thames, H; Yaromina, A | 1 |
| Arias de la Vega, F; Arrazubi, V; Calvo, FA; Contreras, J; de la Torre, A; de Las Heras, M; García-Saenz, JA; Herruzo, I; Prieto, I; Romero, J | 1 |
| Chen, ZG; Huang, D; Shin, DM; Su, L; Wang, D; Zhang, H | 1 |
| Barboriak, DP; Brizel, DM; Carroll, MD; Cleland, E; Craciunescu, OI; MacFall, JR; Muradyan, N; Yoo, DS | 1 |
| Agulnik, M | 1 |
| Brizel, DM; Broadwater, G; Carroll, MD; Clough, R; Craciunescu, O; Dunphy, FR; Esclamado, RM; Hoang, J; Kirkpatrick, JP; MacFall, JR; Peterson, BL; Ready, NE; Scher, RL; Yoo, DS | 1 |
| Bienvenu, S; Chaudhry, MA; Forastiere, A; Gilbert, J; Gillison, M; Higgins, MJ; Rudek, MA; Tsottles, N; Wahl, R; Zhao, M | 1 |
| Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D | 1 |
| Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Abemayor, E; Dennis, M; Dohadwala, M; Dubinett, SM; Elashoff, DA; Lin, Y; Luo, J; Sharma, S; St John, MA; Wang, G | 1 |
| Argiris, A; Ferris, RL; Freilino, ML; Gooding, WE; Grandis, JR; Gross, N; Moskowitz, HS; Thomas, SM | 1 |
| Grandis, JR; Quesnelle, KM; Ratay, MK; Wheeler, SE | 1 |
| Benlyazid, A; Delmar, P; Delord, JP; Hennebelle, I; McLoughlin, P; Rochaix, P; Sarini, J; Thomas, F; Vergez, S | 1 |
| Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L | 1 |
| Ahsan, A; Bradford, CR; Chepeha, DB; D'Silva, N; Eisbruch, A; Helman, JI; Lawrence, TS; Nyati, MK; Ramanand, SG; Tsien, CI; Wolf, GT; Worden, FP | 1 |
| Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S | 1 |
| Ali, A; Candy, PA; Epis, MR; Ganda, C; Giles, KM; Kalinowski, FC; Leedman, PJ; Webster, RJ | 1 |
| Fletcher, EV; Knudson, CM; Love-Homan, L; Martin, SM; Parsons, AD; Simons, AL; Sobhakumari, A; Spitz, DR | 1 |
| Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX | 1 |
| Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S | 1 |
| Grandis, JR; Gubish, CT; He, G; Henry, C; Joyce, S; Lui, VW; Quesnelle, KM; Siegfried, JM; Stabile, LP; Thomas, S | 1 |
| Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L | 1 |
| Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
| Baselga, J; Hammond, LA | 1 |
| Lorusso, PM | 1 |
| Pérez-Soler, R | 1 |
| Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE | 1 |
| Caponigro, F | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Fenyo, D; Gibson, N; Griffin, G; Haley, JD; Hunt, T; Iwata, K; Petti, F; Settinari, T; Thelemann, A | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Harari, PM; Huang, S | 1 |
| Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N | 1 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Baillargeon, GM; Calvo, E; Chin, SF; Hidalgo, M; Irish, J; Kreisberg, JI; Malik, SN; Rowinsky, EK; Santabarbara, P; Siu, LL | 1 |
| Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X | 1 |
| Bhola, NE; Grandis, JR; Gubish, CT; Lui, VW; Mills, GB; Shin, D; Siegfried, JM; Siwak, DR; Thomas, SM; Zhang, Q | 1 |
| Burtness, BA; Forastiere, AA | 1 |
| Chen, EX; Chin, SF; Dancey, J; Eisenhauer, EA; Francis, P; Harvey, L; Klein, M; Pond, GR; Siu, LL; Soulieres, D; Winquist, E; Zhang, W | 1 |
| Agulnik, M; Chen, EX; Chen, H; Chen, S; da Cunha Santos, G; Dancey, J; Dos Reis, PP; Hedley, D; Ho, J; Kamel-Reid, S; Marrano, P; Nicklee, T; Pond, GR; Shyr, Y; Siu, LL; Soulieres, D; Squire, JA; Tsao, MS; Winquist, E | 1 |
| Argiris, A; Grandis, JR; Karamouzis, MV | 1 |
| Gyergyay, F | 1 |
| Allal, BC; Benlyazid, A; Chatelut, E; Courbon, F; Delord, JP; Lefebvre, JL; Rives, M; Rochaix, P; Sarini, J; Thomas, F | 1 |
| Atkinson, DM; Carlson, BL; Clarke, MJ; Jacobson, MS; Kemp, BJ; Lowe, VJ; Mladek, AC; Sarkaria, JN; Trump, DP | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Boehm, AL; Freilino, M; Gooding, WE; Grandis, JR; Johnson, DE; Seethala, R; Sen, M; Wang, S; Wong, SM | 1 |
| Glisson, BS; Johnson, FM; Saigal, B | 1 |
| Arnold, LD; Baker, DA; Barbacci, EG; Davis, JA; Doty, JL; Iwata, KK; Morin, MJ; Moyer, JD; Pollack, VA; Pustilnik, LR; Savage, DM; Sloan, DE; Smolarek, TA; Tsaparikos, KE; Vaidya, MP | 1 |
| Norman, P | 1 |
20 review(s) available for erlotinib hydrochloride and Head and Neck Neoplasms
| Article | Year |
|---|---|
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3 | 2009 |
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines | 2010 |
Advances in EGFR-directed therapy in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2011 |
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines | 2004 |
Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
OSI-774 OSI Pharmaceuticals.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Oncogenes; Quinazolines; Structure-Activity Relationship | 2001 |
33 trial(s) available for erlotinib hydrochloride and Head and Neck Neoplasms
| Article | Year |
|---|---|
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catechin; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Precancerous Conditions; Progression-Free Survival; Protein Kinase Inhibitors; Tea | 2020 |
Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Health Status Disparities; Humans; Male; Middle Aged; Quality of Life; Racial Groups; Response Evaluation Criteria in Solid Tumors; Squamous Cell Carcinoma of Head and Neck; Survival Analysis | 2018 |
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Movement; Cell Proliferation; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Prognosis; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2013 |
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Pain; Quinazolines; Remission Induction; Treatment Outcome | 2013 |
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Topics: Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prospective Studies; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides | 2014 |
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sulindac; Tissue Array Analysis | 2014 |
Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate | 2014 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoglobulin G; Male; Middle Aged; Panitumumab; Receptor, ErbB-3; Squamous Cell Carcinoma of Head and Neck | 2015 |
Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Taxoids | 2016 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate | 2018 |
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retreatment; Treatment Outcome | 2010 |
Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Drug Administration Schedule; Drug Eruptions; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Oropharyngeal Neoplasms; Quinazolines; Radiotherapy Dosage; Salvage Therapy; Survival Rate | 2010 |
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chromatography, Liquid; Docetaxel; Dose-Response Relationship, Drug; Enzyme Induction; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Taxoids | 2011 |
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazoles; Quinazolines; Radiation-Sensitizing Agents; Retreatment; Sulfonamides | 2011 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2012 |
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Area Under Curve; Bevacizumab; Chemoradiotherapy; Cisplatin; Contrast Media; Erlotinib Hydrochloride; Gadolinium DTPA; Head and Neck Neoplasms; Humans; Image Enhancement; Lymphatic Metastasis; Magnetic Resonance Imaging; Microcirculation; Molecular Targeted Therapy; North Carolina; Quinazolines | 2012 |
Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2012 |
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Interleukin-6; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sulindac; Transforming Growth Factor alpha | 2012 |
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis | 2013 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines | 2004 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines | 2007 |
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Topics: Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Skin | 2007 |
Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p21; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Hybridization; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2007 |
95 other study(ies) available for erlotinib hydrochloride and Head and Neck Neoplasms
| Article | Year |
|---|---|
Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.
Topics: Animals; Cachexia; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Head and Neck Neoplasms; Humans; Ligands; Lung Neoplasms; Mice; Parathyroid Hormone-Related Protein; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck | 2022 |
Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mouth Neoplasms; Pyruvate Kinase; Quercetin; Squamous Cell Carcinoma of Head and Neck | 2023 |
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Chalcone; Chalcones; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Necrosis; Squamous Cell Carcinoma of Head and Neck; Triazoles | 2023 |
Localized delivery of Erlotinib using liposomal gel formulations for the treatment of oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Liposomes; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck | 2023 |
Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Hedgehog Proteins; Humans; Phosphatidylinositol 3-Kinases; Squamous Cell Carcinoma of Head and Neck; Wnt Signaling Pathway | 2023 |
Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; CRISPR-Cas Systems; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mechanistic Target of Rapamycin Complex 2; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rapamycin-Insensitive Companion of mTOR Protein; Squamous Cell Carcinoma of Head and Neck | 2019 |
Analyzing expression and phosphorylation of the EGF receptor in HNSCC.
Topics: Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeostasis; Humans; Phosphorylation; Squamous Cell Carcinoma of Head and Neck; Tissue Array Analysis | 2019 |
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Papillomavirus Infections; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Squamous Cell Carcinoma of Head and Neck | 2020 |
Regulatory role of transcription factor HBP1 in anticancer efficacy of EGFR inhibitor erlotinib in HNSCC.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; High Mobility Group Proteins; Humans; Repressor Proteins; Squamous Cell Carcinoma of Head and Neck; Transcription Factors | 2020 |
EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Male; Mice; Middle Aged; Mutation; Proto-Oncogene Proteins c-myc; Squamous Cell Carcinoma of Head and Neck; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Precision Medicine | 2020 |
Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Coculture Techniques; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, SCID; Photochemotherapy; Photosensitizing Agents; Porphyrins; Stereoisomerism; Structure-Activity Relationship; Survival Rate | 2021 |
Mitochondrial pyruvate carrier 1 regulates ferroptosis in drug-tolerant persister head and neck cancer cells via epithelial-mesenchymal transition.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Ferroptosis; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Phospholipid Hydroperoxide Glutathione Peroxidase; Protein Kinase Inhibitors; Retinoblastoma-Binding Protein 2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Indoles; Mice; Mice, SCID; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2021 |
The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Erlotinib Hydrochloride; Head and Neck Neoplasms; Histone Demethylases; Humans; Phosphatidylinositol 3-Kinases; Pyridines; Sulfonamides | 2021 |
How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics.
Topics: Amino Acids; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Isotope Labeling; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Tyrosine | 2021 |
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2018 |
Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Interferon-alpha; Mice; Receptors, Retinoic Acid; Squamous Cell Carcinoma of Head and Neck; STAT1 Transcription Factor; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Is EGFR really a therapeutic target in head and neck cancers?
Topics: Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Radiotherapy, Adjuvant | 2019 |
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Signal Transduction; Tumor Cells, Cultured | 2013 |
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Topics: Autophagy; Carcinoma, Squamous Cell; Cytoprotection; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; HEK293 Cells; Humans; NADPH Oxidase 4; NADPH Oxidases; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2013 |
Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Niclosamide; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor | 2013 |
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Triazoles | 2013 |
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2013 |
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sensitivity and Specificity; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transfection | 2014 |
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction | 2014 |
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Pyrazoles; Quinazolines; Sulfonamides | 2014 |
Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phenotype; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2014 |
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Monensin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2014 |
Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor.
Topics: Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Transforming Growth Factor beta | 2014 |
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Knockout; Mice, Nude; Myeloid Differentiation Factor 88; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Cells, Cultured | 2015 |
Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
Topics: Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Catechin; Cell Line, Tumor; Cycloheximide; Drug Synergism; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Head and Neck Neoplasms; Humans; Membrane Proteins; Phosphorylation; Protein Biosynthesis; Protein Synthesis Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA Interference | 2015 |
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Interleukin-6; Up-Regulation | 2015 |
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Molecular Dynamics Simulation; Phosphorylation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Transport; Signal Transduction | 2015 |
The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2015 |
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carcinogens; Carcinoma, Squamous Cell; Disease Progression; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Quinolones | 2015 |
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Phenotype; Phosphorylation; Predictive Value of Tests; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tongue Neoplasms; Treatment Outcome | 2015 |
Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phosphatidylinositol 3-Kinases | 2016 |
Nuclear EGFR renders cells radio-resistant by binding mRNA species and triggering a metabolic switch to increase lactate production.
Topics: Blotting, Western; Bronchial Neoplasms; Cell Line, Tumor; Cell Nucleus; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lactic Acid; Nuclear Proteins; Oxadiazoles; Protein Kinase Inhibitors; Pyrazoles; Radiation Tolerance; RNA, Messenger | 2015 |
Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1.
Topics: Carcinoma, Squamous Cell; DNA; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Phosphorylation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteomics; RNA Interference; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Tumor Suppressor p53-Binding Protein 1 | 2015 |
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mutation; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Chloroquine; Deoxyglucose; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Female; Glucose; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2016 |
Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53 | 2016 |
Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Mouth Neoplasms; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Telomeric Repeat Binding Protein 2; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytokines; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Inflammation Mediators; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Mice; Prognosis; Protein Kinase Inhibitors; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Transcriptome; Xenograft Model Antitumor Assays | 2016 |
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.
Topics: Antineoplastic Agents; Biomarkers; Cell Nucleus; Cytoplasm; DNA Replication; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Head and Neck Neoplasms; Histone-Lysine N-Methyltransferase; Humans; Immunohistochemistry; Lysine; Methylation; Models, Biological; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Transport | 2017 |
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous | 2008 |
Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; delta-Crystallins; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Homeodomain Proteins; Humans; Mesoderm; Phenotype; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2009 |
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured | 2009 |
Targeting the future in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Catechin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Transcription Factor RelA; Tumor Suppressor Protein p53 | 2009 |
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines | 2009 |
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cisplatin; Commiphora; Drug Synergism; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasm Transplantation; Phytotherapy; Plant Preparations; Pregnenediones; Quinazolines; STAT3 Transcription Factor | 2009 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phosphorylation; Proto-Oncogene Proteins c-cbl; Quinazolines; Ubiquitin | 2010 |
Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Keratoacanthoma; Protein Kinase Inhibitors; Quinazolines; Scalp; Skin Neoplasms; Treatment Outcome | 2010 |
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lignans; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Topics: Aged; Animals; Blotting, Western; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.
Topics: Animals; Carcinoma, Squamous Cell; Cell Cycle; Cell Growth Processes; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2011 |
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Logistic Models; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Tumor Microenvironment | 2011 |
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Protein Stability; Quinazolines; RNA Interference; RNA Stability; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.
Topics: beta Catenin; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Chi-Square Distribution; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Phenotype; Quinazolines; Snail Family Transcription Factors; Transcription Factors; Wound Healing | 2012 |
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.
Topics: Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Carcinoma, Squamous Cell; Carrier Proteins; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
Topics: Adolescent; Adult; Carcinoma, Squamous Cell; Cell Culture Techniques; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Young Adult | 2013 |
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2012 |
Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.
Topics: 3' Untranslated Regions; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Signal Transduction | 2012 |
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Auranofin; Buthionine Sulfoximine; Carcinoma, Squamous Cell; Catalase; Cell Line, Tumor; Cell Survival; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Necrosis; Oxidation-Reduction; Oxidative Stress; Peroxiredoxins; Quinazolines; RNA, Small Interfering; Thioredoxin-Disulfide Reductase; Thioredoxins; Xenograft Model Antitumor Assays | 2012 |
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Transcriptional Activation | 2013 |
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2012 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Chromatography, Affinity; Chromatography, Liquid; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoblotting; Isotopes; Mass Spectrometry; Models, Biological; Peptide Mapping; Phosphorylation; Phosphotyrosine; Proteins; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; src-Family Kinases | 2005 |
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines; Skin | 2007 |
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Invasiveness; Quinazolines; Receptors, Bombesin; Signal Transduction; Tumor Stem Cell Assay | 2007 |
Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Polymerase Chain Reaction; Quality of Life; Quinazolines | 2007 |
[Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2007 |
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Dideoxynucleosides; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2008 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |
Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2008 |
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Taxoids | 2008 |
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Polypharmacy; Quinazolines; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 1999 |